Neutrophil defensin 1

Also known as: Defensin, alpha 1, HNP-1, DEFA1, DEFA1B, P59665

**Mechanism of Action** Neutrophil defensin 1 (HNP-1) is a cationic antimicrobial peptide stored in azurophilic granules of neutrophils. Its primary mechanism involves disruption of microbial membranes via electrostatic interactions with negatively charged phospholipids, leading to pore formation and cell lysis. Additionally, HNP-1 modulates innate immunity by promoting chemotaxis of immune cells, inducing cytokine release, and enhancing antigen presentation through dendritic cell maturation. It also exhibits antiviral activity by interfering with viral envelope integrity and inhibiting viral replication. **Key Research Findings** Preclinical studies demonstrate broad-spectrum activity against Gram-positive and Gram-negative bacteria (e.g., *Staphylococcus aureus*, *Escherichia coli*), fungi (*Candida albicans*), and enveloped viruses (e.g., HIV-1, herpes simplex virus). HNP-1 has been shown to synergize with conventional antibiotics and reduce biofilm formation. In animal models, exogenous HNP-1 improves survival in sepsis and pulmonary infections. However, its therapeutic potential is limited by cytotoxicity at high concentrations and susceptibility to proteolytic degradation. **Clinical Relevance** HNP-1 remains in the experimental stage, with no approved clinical applications. Its role as a biomarker for infectious and inflammatory diseases (e.g., sepsis, cystic fibrosis) is under investigation. Challenges include optimizing delivery systems and minimizing off-target effects. Current research focuses on synthetic analogs with enhanced stability and selectivity. For research purposes only — not medical advice.

Key data

Mechanism of action

Effector molecule of the innate immune system that acts via antibiotic-like properties against a broad array of infectious agents including bacteria, fungi, and viruses or by promoting the activation and maturation of some APCs (PubMed:15616305, PubMed:17142766, PubMed:20220136, PubMed:24236072). Interacts with the essential precursor of cell wall synthesis lipid II to inhibit bacterial cell wall synthesis (PubMed:20214904). Inhibits adenovirus infection via inhibition of viral disassembly at the vertex region, thereby restricting the release of internal capsid protein pVI, which is required for endosomal membrane penetration during cell entry (PubMed:18191790). In addition, interaction with adenovirus capsid leads to the redirection of viral particles to TLR4 thereby promoting a NLRP3-mediated inflammasome response and interleukin 1-beta (IL-1beta) release (PubMed:35080426). Induces the production of proinflammatory cytokines including type I interferon (IFN) in plasmacytoid dendritic cells (pDCs) by triggering the degradation of NFKBIA and nuclear translocation of IRF1, both of which are required for activation of pDCs (PubMed:27031443)

Research & studies

Frequently asked questions

Related peptides